Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Almac Pharma Services Limited
483
•Almac Pharma Services Limited•February 10, 2014

Almac Pharma Services Limited – FDA 483, Feb 10, 2014

Record Details

During an inspection conducted from January 16 to February 10, 2014, the U.S. Food and Drug Administration (FDA) cited P.F.R.immer, Inc., a human drug manufacturer and repackager located in Eatontown, NJ, for multiple significant deviations from current Good Manufacturing Practice (CGMP) regulations, as outlined in an FDA Form 483. The inspection revealed seven observations, many of which were repeat findings from a previous inspection in 2012, indicating persistent systemic issues. Key violations included a failure to adequately investigate Out-of-Specification (OOS) results for Lidocaine HCl 2% Gel, lacking root cause analysis and impact assessment. The firm also failed to follow its written stability testing program by omitting required pH tests for drug lots. Furthermore, P.F.R.immer, Inc. did not test each component, such as Lidocaine HCl, for identity prior to use, instead relying solely on supplier certificates of analysis. Similarly, finished drug products were released without testing for the active ingredient's identity. Additional observations highlighted the absence of cleaning validation for manufacturing equipment and insufficient documentation of cleaning processes, raising concerns about potential cross-contamination. Critical deficiencies in personnel training were noted, with no documented CGMP training for employees in production, quality control, or even the President. Finally, the Quality Control Unit lacked written procedures for its essential responsibilities, including material approval and production record review. These issues collectively indicate a need for comprehensive corrective actions to ensure compliance with 21 CFR regulations and safeguard drug product quality and safety.

Company
Almac Pharma Services Limited
Inspection date
February 10, 2014
Product type
drugs
Office
Baltimore District Office
People
  • Justin A. Boyd (Research Specialist II)
  • Khoa Nathan V. Tran (issuing_officer)
View Company Profile

ID · f2b441bf-7b57-44ee-b50f-81c8bda26648

Other documents for Almac Pharma Services Limited
  • 483 - 2025-11-28November 28, 2025
  • EIR - 2019-09-06September 6, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Almac Pharma Services Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.